2Xideas AG Sells 386 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

2Xideas AG cut its holdings in Charles River Laboratories International, Inc. (NYSE:CRL) by 1.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 36,758 shares of the medical research company’s stock after selling 386 shares during the quarter. 2Xideas AG owned approximately 0.07% of Charles River Laboratories International worth $6,786,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently bought and sold shares of the company. Versant Capital Management Inc lifted its stake in Charles River Laboratories International by 1,071.4% in the fourth quarter. Versant Capital Management Inc now owns 164 shares of the medical research company’s stock worth $30,000 after acquiring an additional 150 shares during the period. Pinnacle Bancorp Inc. raised its holdings in Charles River Laboratories International by 52.0% in the 4th quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company’s stock worth $35,000 after purchasing an additional 65 shares in the last quarter. Pilgrim Partners Asia Pte Ltd purchased a new stake in shares of Charles River Laboratories International in the 4th quarter worth about $48,000. Tortoise Investment Management LLC boosted its stake in shares of Charles River Laboratories International by 77.7% during the 4th quarter. Tortoise Investment Management LLC now owns 263 shares of the medical research company’s stock valued at $49,000 after purchasing an additional 115 shares in the last quarter. Finally, Huntington National Bank increased its position in shares of Charles River Laboratories International by 120.6% during the fourth quarter. Huntington National Bank now owns 300 shares of the medical research company’s stock valued at $55,000 after buying an additional 164 shares during the period. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Insider Activity at Charles River Laboratories International

In related news, COO Birgit Girshick purchased 1,514 shares of the business’s stock in a transaction on Thursday, February 20th. The stock was acquired at an average price of $164.63 per share, with a total value of $249,249.82. Following the completion of the acquisition, the chief operating officer now owns 55,058 shares of the company’s stock, valued at approximately $9,064,198.54. This trade represents a 2.83 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO James C. Foster acquired 6,075 shares of the firm’s stock in a transaction dated Thursday, February 20th. The stock was bought at an average cost of $165.01 per share, for a total transaction of $1,002,435.75. Following the purchase, the chief executive officer now directly owns 183,639 shares of the company’s stock, valued at approximately $30,302,271.39. This trade represents a 3.42 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 1.30% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several research firms have weighed in on CRL. Morgan Stanley cut their price objective on Charles River Laboratories International from $220.00 to $184.00 and set an “equal weight” rating on the stock in a research report on Wednesday, February 5th. Robert W. Baird reduced their price target on Charles River Laboratories International from $177.00 to $173.00 and set a “neutral” rating on the stock in a research note on Thursday, February 20th. Citigroup raised Charles River Laboratories International from a “sell” rating to a “neutral” rating and raised their price objective for the company from $155.00 to $175.00 in a research report on Tuesday, March 4th. Barclays reduced their target price on shares of Charles River Laboratories International from $205.00 to $166.00 and set an “equal weight” rating on the stock in a research report on Tuesday, February 18th. Finally, UBS Group reissued a “neutral” rating and set a $185.00 price target (down from $250.00) on shares of Charles River Laboratories International in a research report on Friday, January 17th. One analyst has rated the stock with a sell rating and sixteen have issued a hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $189.77.

Charles River Laboratories International Trading Down 2.9 %

Charles River Laboratories International stock opened at $136.95 on Friday. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.41 and a quick ratio of 1.14. The stock has a market capitalization of $7.00 billion, a PE ratio of 912.99, a price-to-earnings-growth ratio of 4.54 and a beta of 1.45. The business’s fifty day moving average is $162.49 and its 200 day moving average is $180.77. Charles River Laboratories International, Inc. has a one year low of $132.99 and a one year high of $258.56.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings data on Wednesday, February 19th. The medical research company reported $2.66 earnings per share for the quarter, beating the consensus estimate of $2.50 by $0.16. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The firm had revenue of $1 billion during the quarter, compared to analysts’ expectations of $983.63 million. During the same period in the previous year, the company earned $2.46 earnings per share. The firm’s quarterly revenue was down 1.1% on a year-over-year basis. On average, sell-side analysts predict that Charles River Laboratories International, Inc. will post 9.36 EPS for the current year.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).